Cannabigerol (CBG) In The Treatment Of Seizures And Epilepsy

Tech ID: 32966 / UC Case 2022-512-0

ABSTRACT

Researchers at the University of California, Davis have developed a method of treating or mitigating seizure, treating epilepsy, as well as a method of reducing the frequency of seizures, using cannabigerol or dihydrocannabigerol and analogs thereof.

FULL DESCRIPTION

Cannabidiol (CBD), a biologically active constituent of the cannabis (hemp) plant, has been approved for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Using a standard model in the identification of antiseizure agents, CBD has been shown to protect against tonic hindlimb extension (THLE). Although CBD has been extensively studied, many other plant cannabinoids, including cannabigerol (CBG) and cannabichromene (CBC) previously have not been assessed for potential utility in epilepsy therapy.

Researchers at the University of California, Davis, have assessed cannabigerol (CBG) and cannabichromene (CBC) for potential utility in epilepsy therapy. Utilizing a well-validated model to identify antiseizure agents, they have developed a method of treating or mitigating seizure, treating epilepsy, as well as a method of reducing the frequency of seizures via a therapeutically effective compound of formula.

APPLICATIONS

- Treating or mitigating convulsant effects
- Treating or mitigating seizures
- Treating or mitigating epilepsy

FEATURES/BENEFITS

- Reducing the frequency of seizures
- Potential to benefit large population of epilepsy patients

PATENT STATUS

Patent Pending